Brookfield life sciences spin-off ARC has secured two new leasing deals at its Oxford cluster.
MiroBio, a biotech company which was born at the University of Oxford and acquired by Gilead Sciences in August last year, has signed for 9,500 sq ft at Building 9400. The move follows £80m of venture capital raised in June last year, the largest early-stage funding round completed in the region in 2022.
An existing tenant, Accession Therapeutics, has also signed for new space, expanding by 30% and adding 5,700 sq ft at Building 7400. The immune-oncology therapeutics developer is currently based in Building 7600. Its £18.5m early-stage venture capital funding round completed in November 2022 was also among the five largest fundraisings recorded in Oxford over the past year.
Dan Williams, director of asset management at ARC Oxford, said: “Our community of life science organisations is expanding at ARC Oxford. This is testament to Oxfordshire’s science and tech ecosystem, and our investment into the campus is creating laboratory space that fosters innovation and allows our members to continue their growth journey in today’s global economy.”
The deals come shortly after Brookfield had rebranded the site as ARC Oxford, which was formerly known as Oxford business park, and committed to invest more than £1bn in the region by late 2020s.
Other occupiers at ARC Oxford include Perspectum, Ivy Farm, and Oxford Biomedica.
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
